Sanara Medtech Inc
NASDAQ:SMTI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
26.86
41.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sanara Medtech Inc
Net Margin
Sanara Medtech Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | US |
| Market Cap | 329.6m USD |
| Net Margin |
-11%
|
| Country | JP |
| Market Cap | 6.8T JPY |
| Net Margin |
24%
|
| Country | CH |
| Market Cap | 37.9B CHF |
| Net Margin |
12%
|
| Country | DK |
| Market Cap | 200.9B DKK |
| Net Margin |
19%
|
| Country | US |
| Market Cap | 16.9B USD |
| Net Margin |
11%
|
| Country | KR |
| Market Cap | 9.9T KRW |
| Net Margin |
-358%
|
| Country | CA |
| Market Cap | 6.9B USD |
| Net Margin |
-8%
|
| Country | CN |
| Market Cap | 48.6B CNY |
| Net Margin |
42%
|
| Country | US |
| Market Cap | 6.3B USD |
| Net Margin |
29%
|
| Country | US |
| Market Cap | 6.1B USD |
| Net Margin |
9%
|
| Country | UK |
| Market Cap | 4.8B GBP |
| Net Margin |
7%
|
Sanara Medtech Inc
Glance View
Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 63 full-time employees. The Company’s products include surgical wound care products, which includes CellerateRX Surgical Activated Collagen (Powder and Gel), and chronic wound care products, which include HYCOL Hydrolyzed Collagen (Powder and Gel), BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel. The surgical wound care products are used in specialties including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, oncology, plastic/reconstructive, podiatric, urology and vascular. The chronic wound care products are used across the post-acute continuum of care, including home health, hospice, physician offices, podiatrists, retail, skilled nursing facilities, and wound care centers.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Sanara Medtech Inc's most recent financial statements, the company has Net Margin of -10.7%.
You don't have any saved screeners yet
